Passage Bio Inc.

Passage Bio and Remix Therapeutics Announce Merger to Advance REM-422, an Oral mRNA Degrader Targeting MYB in Cancer

- Passage Bio and Remix Therapeutics have entered into a definitive all-stock merger agreement, with the combined company operating as Remix Therapeutics and trading on Nasdaq under "RMTX." - Remix's lead program, REM-422, is an orally available mRNA degrader targeting the historically undruggable transcription factor MYB, currently in Phase 1/2 trials for ACC, AML, and HR-MDS. - A concurrent oversubscribed $100 million private placement led by Decheng Capital is expected to fund operations into 2028, supporting multiple clinical readouts for REM-422 in 2027. - The combined company will be led by Remix CEO Peter Smith, with the transaction expected to close in the fourth quarter of 2026.